Molnupiravir and nirmatrelvir-ritonavir combination therapy should be considered for patients within 5 days of symptom onset.
News and Features
Review and meta-analysis show improvements in functional exercise capacity vs standard of care.
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
No variation in risk for PCC seen based on number of vaccinations, but previous infection linked to reduced PCC risk.
Xacduro is available as a kit containing a single dose vial of sulbactam 1g and 2 single-dose vials of durlobactam (0.5g in each vial).
By simplifying the dosing regimen, the Company hopes to improve patient adherence and treatment outcomes.
The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study compares Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products.
Incident hypertension, statin use higher with tenofovir alafenamide fumarate compared with tenofovir disoproxil fumarate.
New booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
Interim analysis showed that the mRNA-1010 vaccine met all coprimary endpoints.
Shorter disease course with less mucosal disease seen on reinfection vs initial infection.
Interim data show vaccine effectiveness of 51.9% in 5 South American countries during their flu season.
The bivalent Pfizer-BioNTech and Moderna COVID-19 vaccines are no longer authorized for use in the United States.
Recurrent respiratory papillomatosis is caused primarily by HPV types 6 and 11.
Spike in severe cases seen in Florida and Georgia; regional increases usually predict the beginning of RSV season, according to CDC
The BA.2.86 variant has multiple genetic differences from previous versions of SARS-CoV-2.
With fall on the horizon, MPR sat down with Dr Abdul-Mutakabbir, PharmD, MPH, Assistant Professor of Clinical Pharmacy at the University of California San Diego to discuss the new COVID-19, flu and RSV vaccines, vaccine hesitancy, health equity and representation in medicine.
Cancer patients were more likely to die from the BA.1 and BA.2 omicron variants of SARS-CoV-2 than from wild-type SARS-CoV-2, data suggest.
Those who survived COVID-19 had reduced mortality on days 181 to 365 and 366 to 730.